Pre-made Fidasimtamab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1;ERBB2/HER2 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-667

Pre-Made Fidasimtamab biosimilar, Whole mAb, Anti-PDCD1/PD-1;ERBB2/HER2 Antibody: Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-667-1mg 1mg Inquiry
GMP-Bios-ab-667-10mg 10mg Inquiry
GMP-Bios-ab-667-100mg 100mg Inquiry
GMP-Bios-ab-667-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Fidasimtamab biosimilar, Whole mAb, Anti-PDCD1/PD-1;ERBB2/HER2 Antibody: Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
INN Name Fidasimtamab
TargetPD-1;HER2
FormatBispecific Whole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1;IgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD
99% SI StructureNone;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC
95-98% SI StructureNone;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL
Year Proposed2021
Year Recommendedna
CompaniesHanmi Pharmaceutical;Innovent Biologics
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna